Kyongbo Pharmaceutical Co Ltd (214390) — Cash Flow-to-Debt Ratio
Kyongbo Pharmaceutical Co Ltd (214390) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of ₩4.51 Billion could theoretically repay 0% of its total liabilities (₩171.21 Billion) in one year. See 214390 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kyongbo Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Kyongbo Pharmaceutical Co Ltd across 11 annual periods. Also explore Kyongbo Pharmaceutical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Kyongbo Pharmaceutical Co Ltd (2014–2024)
Year-by-year debt coverage analysis for Kyongbo Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Kyongbo Pharmaceutical Co Ltd (214390) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.00x | ₩149.12 Million | ₩137.73 Billion | ▼ -97.3% |
| 2023 | 0.04x | ₩4.84 Billion | ₩121.92 Billion | ▼ -62.0% |
| 2022 | 0.10x | ₩10.13 Billion | ₩96.84 Billion | ▼ -46.9% |
| 2021 | 0.20x | ₩17.97 Billion | ₩91.28 Billion | ▼ -8.0% |
| 2020 | 0.21x | ₩20.80 Billion | ₩97.18 Billion | ▼ -19.8% |
| 2019 | 0.27x | ₩23.67 Billion | ₩88.65 Billion | ▲ +1803.2% |
| 2018 | -0.02x | ₩-1.14 Billion | ₩72.61 Billion | ▼ -103.8% |
| 2017 | 0.41x | ₩25.81 Billion | ₩63.36 Billion | ▲ +19.5% |
| 2016 | 0.34x | ₩25.33 Billion | ₩74.33 Billion | ▲ +484.0% |
| 2015 | 0.06x | ₩4.24 Billion | ₩72.67 Billion | ▼ -63.7% |
| 2014 | 0.16x | ₩16.04 Billion | ₩99.70 Billion | — |